Caution urged on off-label ketamine

IT'S too early to recommend ketamine as a treatment for depression despite promising results from preliminary trials, says an Australian clinical and research psychiatrist.

Concerned that strong public demand may prompt off-label use of the drug, she says efficacy and safety has yet to be properly tested.

Writing in the MJA, Professor Colleen Loo from the